Differential impact of biologic therapy on heart function biomarkers in rheumatoid arthritis patients: Observational study on etanercept, adalimumab and tocilizumab

Conclusion As this biomarker reflects potential heart injury we suggest that heart damage proceeds in continuous manner in RA patients despite effective treatment and attainment of remission/low disease activity. This finding however should be verify in larger cohort of RA patients to ascertain if routine assessment of H-FABP may be useful for detection of patients with RA who are at risk of development of heart damage.PMID:35638285 | DOI:10.2174/1381612828666220527141532

Source: Current Pharmaceutical Design - May 31, 2022 Category: Drugs & Pharmacology Authors: Beata Dubiel-Braszczok Karolina Nowak Aleksander Owczarek Ma łgorzata Engelmann Olga Gumkowska-Sroka Przemys ław J Kotyla Source Type: research